The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS

被引:281
|
作者
Parker, JE [1 ]
Mufti, GJ [1 ]
Rasool, F [1 ]
Mijovic, A [1 ]
Devereux, S [1 ]
Pagliuca, A [1 ]
机构
[1] Guys Kings Thomas Sch Med, Dept Haematol Med, London SE5 8RX, England
关键词
D O I
10.1182/blood.V96.12.3932.h8003932_3932_3938
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bone marrow CD34(+) cell apoptosis (annexin V), proliferation (Ki-67), and Bcl-2-related protein expression was evaluated by flow cytometry in 102 patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia secondary to MDS (MDS-AML) and in 30 normal donors (NBM). Apoptosis was significantly increased in refractory anemia (RA)/RA with ringed sideroblasts (RARS) (56.9% [20.4%-93.6%]) and refractory anemia with excess blasts (RAEB) (51.2% [25.2%-76.6%]) compared with NBM (16.7% [3.4%-35.3%], P < .0001). In RA/RARS, apoptosis always exceeded proliferation (Ki-67-positivity, 26.1% [9.5%-47.8%]; apoptosis: proliferation ratio 2.08 [1.15-3.63]); whereas in RAEB, this ratio equalized (1.14 [0.93-2.08]) due to increased proliferation (40.4% [22%-69.5%]). Progression to RAEB in transformation (RAEB-t)/MDS-AML was associated with a significant reduction in apoptosis (22.3% [2.1%-53.2%]; P < .0001) and proliferation (16.8% [1.9%-75.8%] P = .04; ratio 1.69 [0.16-12.21]), Pro-apoptotic (Bax/Bad) versus anti-apoptotic (Bcl-2/Bcl-X) Bcl-2-related protein ratios were increased in RA/RARS compared with NBM (2.57 [1.93-9.42] versus 1.89 [0.65-4.1]; P = .06), whereas disease progression was associated with significantly reduced ratios (1.16 [0.06-3.32]; P < .0001) due primarily to increased Bcl-2 expression. Apoptosis and Bax/Bad:Bcl-2/Bcl-X ratio were inversely correlated with both International Prognostic Scoring System score and cytogenetic risk group; highest levels observed in patients with low score and/or good risk cytogenetics. There was a trend toward an association between Bcl-2-related protein expression and apoptosis (P = .07). This study indicates that MDS progression arises through multiple hits that alter levels of CD34(+) cell apoptosis and proliferation. Early disease is associated with excessive apoptosis and elevated ratio of apoptosis to proliferation. Increased proliferative rates are observed in RAEB, whereas leukemic transformation arises through inhibition of apoptosis rather than excessive cell growth. Although disease progression is accompanied by a fall in pro-apoptotic versus anti-apoptotic Bcl-2-related protein ratios, heterogeneity in patterns of protein expression indicates that factors additional to Bcl-2 family members play a role in the deregulated apoptosis in MDS. (C) 2000 by The American Society of Hematology.
引用
收藏
页码:3932 / 3938
页数:7
相关论文
共 50 条
  • [21] ROLE OF RIBOSOMAL GENES IN MYELODYSPLASTIC SYNDROMES EVOLUTION TO ACUTE MYELOID LEUKEMIA
    Santiago, S.
    Isabel, I.
    Karen, K.
    Miguel, G.
    Rosa, R.
    Francisco, F.
    Mar, M.
    Joaquin, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 374 - 375
  • [22] Role of the BH3 (Bcl-2 homology 3) domain in the regulation of apoptosis and Bcl-2-related proteins
    Lutz, RJ
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2000, 28 : 51 - 56
  • [23] Polycomb Group Proteins in Myelodysplastic Syndromes and Its Transformation Into Acute Myeloid Leukemia
    Shen, Hongjie
    Chen, Zi-Xing
    Cen, Jiannong
    Wang, Yuanyuan
    He, Jun
    BLOOD, 2009, 114 (22) : 698 - 698
  • [24] Polycomb group proteins in myelodysplastic syndromes and its progression to acute myeloid leukemia
    Chen, Zi-Xing
    Shen, Hong-jie
    Cen, Jian-nong
    Wang, yuan-yuan
    He, Jun
    Qi, Xiao-fei
    CANCER RESEARCH, 2010, 70
  • [25] Inhibition of UBE2N As a Therapeutic Approach in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
    Barreyro, Laura
    Sampson, Avery M.
    Bolanos, Lyndsey
    Niederkorn, Madeline
    Pujato, Mario
    Smith, Molly A.
    Tomoya, Muto
    Haffey, Wendy D.
    Christie, Susanne
    Liu, Xiaona
    Weirauch, Matthew
    Greis, Ken
    Seibel, William L.
    Starczynowski, Daniel T.
    BLOOD, 2016, 128 (22)
  • [26] Population pharmacokinetic modelling of decitabine in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
    Mistry, B.
    Gibiansky, L.
    Hussein, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Intensive chemotherapy for patients with high risk myelodysplastic syndromes (MDS) and acute myeloid leukemia.
    Shi, J
    Shao, ZH
    Liu, H
    Chen, GB
    Song, LY
    Zhang, YZ
    Li, K
    Fu, R
    Zhao, MF
    He, GS
    Bar, J
    Chu, YL
    Yang, TY
    BLOOD, 2002, 100 (11) : 336B - 336B
  • [28] PHF6 Somatic Mutations and Their Functional Role in the Pathophysiology of Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
    Przychodzen, Bartlomiej P.
    Gu, Xiaorong
    You, Dewen
    Hirsch, Cassandra M.
    Clemente, Michael J.
    Sekeres, Mikkael A.
    Nazha, Aziz
    Makishima, Hideki
    Maciejewski, Jaroslaw P.
    BLOOD, 2016, 128 (22)
  • [29] CHROMOSOMAL STUDIES IN 24 PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIAS (AML) AND MYELODYSPLASTIC SYNDROMES (MDS)
    WEH, HJ
    HOFFMANN, R
    SUCIU, S
    KUSE, R
    HOSSFELD, DK
    BLUT, 1987, 55 (04): : 236 - 236
  • [30] EXTRAMEDULLARY LEUKEMIA (EML) IN MYELODYSPLASTIC SYNDROMES (MDS) - NOT A TRUE INDICATION OF IMPENDING ACUTE MYELOID-LEUKEMIA (AML)
    EDENFIELD, WJ
    BYRD, JC
    AYLESWORTH, C
    DOW, NS
    DAWSON, N
    BLOOD, 1994, 84 (10) : A631 - A631